A Phase I Open Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients with Optic Nerve Athrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuopathy (NAION) (Stratum II)